Arformoterol

Arformoterol
Clinical data
Trade names	Brovana
Other names	Arformoterol tartrate (USAN US)
AHFS/Drugs.com	Monograph
MedlinePlus	a602023
License data	US DailyMed: Arformoterol;
Routes of; administration	Inhalation
ATC code	None;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	52–65%
Elimination half-life	26 hours
Identifiers
	IUPAC name N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide;
CAS Number	67346-49-0 ;
PubChem CID	3083544;
IUPHAR/BPS	7479;
DrugBank	DB01274 ;
ChemSpider	2340731 ;
UNII	F91H02EBWT;
KEGG	D07463; D02981;
ChEBI	CHEBI:408174 ;
ChEMBL	ChEMBL1201137 ;
CompTox Dashboard (EPA)	DTXSID1023077 DTXSID40110071, DTXSID1023077 ;
Chemical and physical data
Formula	C19H24N2O4
Molar mass	344.411 g·mol−1
	InChI InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1 ; Key:BPZSYCZIITTYBL-YJYMSZOUSA-N ;
	(what is this?) (verify)

Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD).^[1]^[2]

It is a long-acting β₂ adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol.^[1] It was approved for medical use in the United States in October 2006.^[1] It is available as a generic medication.^[3]

^ ^a ^b ^c ^d "Brovana- arformoterol tartrate solution". DailyMed. 13 May 2021. Retrieved 4 March 2022.
^ Loh CH, Donohue JF, Ohar JA (March 2015). "Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease". Expert Opinion on Drug Safety. 14 (3): 463–72. doi:10.1517/14740338.2015.998196. PMID 25563342. S2CID 7767810.
^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.